i don't think, frankly, that the regulators are as keen on novavax as is novavax on novavax i don't recommend this stock let's go to andrew in michigan andrew >> caller: jimmy chill >> what's happening? >> caller: i need to give you an undefeated michigan state boo-yah! >> wow >> caller: jim, i've been watching your show since i was a student at michigan state 13 years ago. i started the investing club emails this week and i wanted to tell you it is the best thing you have ever done for your followers. >> you are too kind. i should have done a club like this years ago i don't want your money. i don't want your commissions. i want to teach. i've got the right thing thank you very much. i want to teach at michigan state. let me go. let me go back there i want to go back to michigan and do some teaching >> caller: it's the best we appreciate the honesty. i look forward to it every day >> many more to come another bulletin preparing during commercial. what's happening >> caller: can't wait. the stock i'm calling about has pulled back about 20% from the high traiting at a pe below the ma

now the novavax vaccine looks promising.is just lagging behind in terms of getting the submission to the fda and other regulatory agencies around the world and getting it authorized or eventually licensed. and then, of course, there has to be tested now in younger age groups, just like the mrnas have been. so it is a good question. very understandable. but it is going to be a bit of a delay before you see novavax that is out there for this age group. >> dr. paul spearman, we appreciate the help you've given us answering these questions. >> thank you very much. good to be on the show. >>> so we have a remarkable new interview, don lemon spoke exclusively with seven members of the jury in the derek chauvin murder trial. >>> and also moments away now from a critical gdp report. we're going to bring you the numbers next. when did you see the signs? when i needed to create a better visitor experience. improve our workflow. attract new customers. that's when fastsigns recommended fleet graphics. yeah, and now business is rolling i

this has been an absolute roller coaster for this company over the course of the pandemic novavax was its stock was close to veero and it's run up incredibly as the power of the vaccine technology has been proven phase 3 results showed more than 90% efficacy but the manufacturing problems causing delays in them getting the vaccine out. >> in the meantime, headlines about the white house's plan to quickly immunize kids 5 to 11 in covid. of course, this will be the pfizer vaccine how quickly can that ramp and how does it speak to the supply dynamics already on the market globally >> reporter: so, we're expecting this to happen over the next few weeks. fda advisory committee meeting next week for kids november 2nd and 3rd, cdc advisors meet and are expecting the vaccine will become available widely after that. so, they're putting in place how it will become available it's a lower dose and will have different packaging. having that ready to go as soon as the regulatory green lights are given is the plan. and they're talking about whether they're going to do vaccinating, in pediatrician of

>> we haven't even talked about johnson & johnson, novavax or others, the ability to take share goingant i would say the two mrna vaccines are more alike than different. the moderna vaccine did not typically hit the end point and pfizer's did although i do expect the fda and recommendations for boosters for at-risk people to not really differentiate between the two. but it is clear going forward from a commercial perspective, the booster is going to be key >> getting it to this $5 billion of perpetual sales figure doesn't add up i wanted to ask you about the biden administration, where the chief scientific officer says about moderna, we expect them to stand up as a company in making this vaccine more available to the worlds but it would seem important that they have a strong relationship with the government, which is basically calling a lot of the shots here in terms of the vaccines. >> yeah. no, two great points kelly i would say the first thing is -- i would -- the vaccines are very similar to other pharmaceutical products that, you know, you see good price point in the you were, u.

a lot of the vaccine makers are seeing some weakness the context here is companies like novavax, moderna, pfizer, biontech have seen nice rallies because of their covid vaccines or covid vaccine candidates, but in this session novavax is down 16%. moderna is down 11%. pfizer is off 1%, and biontech, pfizer's partner in its covid vaccine, off 9% right now. kelly, watch the ripple effects for merck. we will see if it carries through. again, many of the vaccine makers or vaccine candidate makers have done very well up until this point here, giving back some of the gains today back over to you >> yeah, we've heard the huge debates about what to do with them now, dom. >>> stocks generally are holding on to gains following the positive news about merck's covid drug could better covid and economic data give us an october to remember in a good way this year joining me is barry james, president and portfolio manager at james investment research great to have you back you have been cautious about some of the headwinds for the market this year what is your thinking now, now that we've had this rese

we've had johnson & johnson, we've had moderna, we've had pfizer, we've had novavax, we've had so many different breakthroughs that are off the charts spectacular i think what's happening is that people still don't feel comfortable. and i don't want to make it a political thing, but i think the government and the administration really doesn't make you feel overwhelmingly confident about getting back out there. so we could have three more of these things that really attack it, and you have to start getting back into the psyche once that happens, then i think we're off to the races the market's had an unlimited amount of things to worry about. china, seasonality i heard sarah on her show talk about -- and thank god she wasn't in the hospital, that's how she phrased it, and that's the truth. i don't know if it takes it off the table. what's the percentages, 50%? so that's flipping a coin. so i think you stated it properly in the beginning of the show, where you said everything but a cure and that's what we're heading towards. but i think you need better than a 50% rate to make people rush

meg tirrell with the latest details on novavax and abbott labs we've got covid vaccines and testing.avax heading lower today after a "politico" report last night citing anonymous sources suggesting the company is having major manufacturing issues that puts in jeopardy the availability of that vaccine both here and around the world, which is really disappointing from a global vaccine access standpoint because this was a vaccine that was really supposed to help with the global effort so the stock down nearly 16% the company saying that it has confidence in its manufacturing and its ability to deliver this vaccine, saying that it plans to file for emergency use authorization in the u.s. by the end of the year. but, of course, this weighing on the stock. and we've seen multiple delays from this company already. abbott labs beating expectations with its third quarter results today, and positing just a blow-away number, $1.9 billion in covid testing revenue for the quarter, forecasting up to 1.4 b 1.4 billion in the fourth quarter. a lot of this driven by the rapid testing sales. binax now

in i the past few minutes, the government has announced that 15,000 people who took part in the novavaxg to be eligible for two doses of the pfizerjab. now, this is significant because that vaccine, although it is highly effective, it hasn't yet been approved by the mhra or indeed any health agencies, and although the uk recognises it, because it is highly effective, other countries don't. so those trial volunteers have said they feel in limbo, they haven't been able to travel. but now they are going to be eligible for two doses of pfizer, and as a result, eight weeks apart, that limbo will be ended, and on the travel pass it will show that they have at two pfizer shots. and that is really important, because these people are the unsung heroes of the pandemic and without them we wouldn't have any vaccines, so important that issueis any vaccines, so important that issue is now finally resolved. interesting. thank you, fergus walsh. the energy regulator has warned that millions of households face significantly higher bills from april when the current price cap is reassessed. the business s

novavax, one of the worst performers, off by a whopping 10%.heir vaccine manufacturing may not be up to snuff, so that is going to wind up hurting that stock. bitcoin talking about record highs. the bitcoin etf over 4%. tons of liquidity buying coming in for that etf as well. i love that idea, there is no alternative. resistance is futile. go buy stocks. guy: that seems to be quite represented on wall street you saw it in the bank of america fund managers survey yesterday. concerned about slowing growth and the idea that there is still this wall of money out there, as a result of which, what is the option? there is no alternative. let's get back to that news regarding the bundesbank. bundesbank resident jens weidmann to step down. the current german chancellor angela merkel says his successor will be chosen by the next coalition. here was the latest, bloomberg's central bank reporter carolyn . what impact is this going to have on policy? do we have an idea of who the successor is likely to be? reporter: weidmann's resignation is a pivotal momen

novavax, moderna, pfizer all down. china saying -- australia sang china's vaccine is getting approved ahead of their reopening. let's look at another deal catching some news. we talked about how the reopening trait is losing steam. it turns out it is bid hitting zoom shares where it kills about one third of that value. why is the stock up. analysts say they are good standalone companies. traders saying we think it is a fair bet. though shares up higher. i want to end with crypto stocks. you cannot do a market check without thinking about bitcoin. overdosed to a deviation moves. look what is doing to some of the stocks. merit, riot, coinbase all up in sympathy. let's see if it continues. alix: i do markets without bitcoin a lot, but i respect you keep doing them. monday china markets are closed for golden week. opec and non-opec meetings will happen on monday. that huge. there are calls for opec to ramp up its production of 400,000 barrels of oil a day. bless you get a touring conference in manchester. earnings coming o

. >>> novavax also in the red today. i shouldn't say also i joins the restaurant groups.15 ores on reports its having trouble meeting fda quality standards for its covid-19 vaccine learn more at james kram ir's investing club go to the website or point your phone at the qr code. >> it is time for -- yes, the animation rolls, the music sounds trading nation chinese stocks making a surprise comeback this month. billy billy, alibaba -- i want there to be a chart with about about and o'reilly auto parts. you got it, about about o'reilly an obscure who reference anded by you soring in october this as the chinese economy slows. at its weakest pace in a year. should the bounce be believed. we asked our trading nation team ava, can i trust the bounce in chinese stocks is it time to lag a little money in >> we would say no we would advocate no more than a small risk speculative position when it comes to china we are tracking 170 entrepreneurial chinese companies of which our holdings appreciated 11% year to date much of it is because of the overreaction we saw early in september.

novavax down 15% pfizer and astrazeneca down.t also sent classic reopening plays higher including cruiselines and airlines 17% gains for united 4.5% for royal caribbean let's begin with the muse out of new york, whether it is a game changer in the fight against quid meg tirrell. >>cally, these results blue expectations out of the water. scott gottlieb this morning calling them phenomenal, a potential game changer for really the psychology of how we think about this, that there could be a drug that's easy to take early on in the course of infection that could have a big impact the impact was that it reduced the risk of hospitalization or death by almost 50% in people who took it within the first five days of symptom onset this was strikingly positive in a the independent data committee overseeing the trial said you have got to stop this and you have got to file with it the fda. merck said they checked with the fda, which agreed is they are going the file for emergency use authorization as soon as possible how do they measure that

. >> novavax and moderna down on the news it is a reminder of the days in the middle of the pandemic doubt if you hadn't just been down 5% in a few weeks have this move but definitely taken to be positive and helping to drive which stocks are working today if you go toward -- if you're big cautious talking point going into next year was the u.s. is bumping up against a hard ceiling of vaccination rates, maybe brace for something into winter this removes that the idea to attack it on multiple fronts and it's something like normal. it is not like november of 2020 with the pfizer vaccine news and already had no idea if we were going to get free of this ever so this is a little bit more modest and encouraging for the economic outlook. >> reference there looking at live pictures of the president arrived on capitol hill for ongoing negotiations we'll see if there's anything to come out of those as the day goes on. paul, how important is d.c. to the markets at the moment? >> i think short term very important. we saw what happened in 2011 when we had the issues with the debt ceiling and then

. >> moderna, novavax and the like. neil: right. >> i also want to point out you have outperformance when you have good news to drive your stock today, for instance, tesla which we'll talk about later on today. i think they're, i think everything isn't terrible just yet. it depend what is happens in d.c. over the next few weeks. neil: that is a good point. tesla is like a technology play. look at it as a auto play. it really is a technology play. susan, i will have you here the hour. >> great to see you. neil: susan li following these developments here. when the president made comment, i need 50 votes. i have 48. clear reference he doesn't have joe manchin with him of west virginia and kyrsten sinema, two holdouts. moderates saying they're not the problem, president caving to the progressives. always in the eyes of beholder. it stymies up the process. where are we on this. let's go to chad pergram with the latest. reporter: senate majority leader chuck schumer told democrats in a letter this morning quote, we must get a

novavax is going to speak at a private meeting. it's a company dedicated to crypto.the this is april 1999, you know, january 2000 or, you know, or hr. 2000 right -- march 2000 right before the internet bubble burst. but there is a lot of movement in this space, and you get the feeling it could go on for a while including that technical aspect where i say a lot of people are hoarding the bitcoin, and you have these positive developments. and the last time that happened, it doubled in price. that's why a lot of people are predicting 100,000, neil. back to you, and the people in l.a. say hello. i ran into a couple of your fans last night. you actually do have fans, believe it or not. neil: write down their names. thank you, hi friend, very much. [laughter] fancy milken conference going on in l.a. by the way, the process behind this etf offering, there are others lining up like planes at laguardia. we've got those that are looking to have funds of their own, i don't believe those are futures funds though. these are just plain if, you know, dabble in sort of a combination

. >>> novavax is down reporting vaccination issues what is happening here it starts off about 21%. >>nical results looks good, 90% efficacy for the company they were resurrected from the brink. they showed it could be detailed which is simmering for a while they are doing it to have what it needs what is concerning about this beyond the company, itself, is this vaccine is important for the global effort of vaccinating the world. they've made promises, if they cannot get it manufactured in a pure enough way in a large enough doses, that will deal a blow to the noble vaccination effort so we have been seeing this delay in manufacturing quarter of quarter, it get pushed back this company does not yet have emergency use authorization despite having the phase 3 results months ago, that look really good. this is a protein vaccine, so it presents a few technology, one more familiar for vaccines it's the one that smith klein is also working on. so it's a real disappointment from a equity standpoint and no have vax' shareholders, who are seeing another delay here, potentially into next year if

both novavax and moderna shares were down. people are thinking, okay.the vaccines what do you think? >> i don't think the pill is a replacement. the pill will be very effective helping to treat people. they've authorized the infection. people who don't choose to get vaccinated or can't get vaccinated the first line of defense may be therapeutics as opposed to vaccines this pill in particular looks like it could be a pan coronavirus therapeutic and that it could work against any r respiratory pathogen that begins with rna it is a very profound treatment effect that's why people are so optimistic you saw a profound treatment effect from those at risk and were well into the course. already symptom magnetic with at least five days or up to five days of treatment and you still saw a very big treatment effect in terms of hospitalization. >> presuming if you could move this earlier and also use it milder patients. you'll see even more profound treatment effect also, will are there people that shouldn't take the pill? >> these are people with one or morris bein

there is a new vaccine called novavax that does not use the mrna technology.hink people are going to go for that one. it is 90% effective, so i think more people will get that vaccine because they are not afraid of it. it is more like a flu shot. also, there is no such thing as a stress free life. if you are that delicate, maybe you should not have been born. also, as far as i'm concerned, psychology is a junk science based more on peer pressure and opinions than hard facts. host: let's get a response from our guest. guest: obviously, i don't agree with the last part, but the point that the caller made about our ability to handle stress i think is actually a really good point. the reality is, we talk about stress for two reasons. i look at it from two perspectives. one is a it is important to know what is actually happening in the population. we have documented that. others have documented that. we also know that over time, if we are under chronic stress, it shows up in both our mental help -- health and physical health. for example, right now, we know that ab

there is a new vaccine called novavax that does not use the mrna technology.hink people are going to go for that one. it is 90% effective, so i think more people will get that vaccine because they are not afraid of it. it is more like a flu shot. also, there is no such thing as a stress free life. if you are that delicate, maybe you should not have been born. also, as far as i'm concerned, psychology is a junk science based more on peer pressure and opinions than hard facts. host: let's get a response from our guest. guest: obviously, i don't agree with the last part, but the point that the caller made about our ability to handle stress i think is actually a really good point. the reality is, we talk about stress for two reasons. i look at it from two perspectives. one is a it is important to know what is actually happening in the population. we have documented that. others have documented that. we also know that over time, if we are under chronic stress, it shows up in both our mental help -- health and physical health. for example, right now, we know that ab

it's companies that we wouldn't -- many of us didn't know about much a year ago, beon tech, moderna, novavaxof the life or death race for the covid-19 vaccine" thanks for your time. >>> coming up on the other side of this break, the ceo of hp inc. on the global ship shortage and the log jam hittg minsoany companies. we'll break it all down with him right after this this morning later this morning, hpce enrique is participating in the quarterly just conference call allowing investors and the public to ask ceos about non-financial investments and ranked 16 in the just 100 rankings of noorn 900 companies it attracts. first hcbo here with us to talk about spli upply chain challengs and more great to see you this morning. we're all trying to understand what the supply chain actually looks like in practice on a day-to-day basis why don't you just tell us how you're seeing it across the board, and maybe we can get into the chip shortage itself >> thank you, and good morning and thank you for having me here first of all, i think first thing we need to understand is with the current shortages the fir

merck up, moderna, novavax down. >> that's continuing today. the news came out on friday. reopening plays also doing well as well, i think. the merck, that experimental -- stuart: oh, the pill. >> cutting 50% of deaths. which is great. stuart: all right. we are now six and a half minutes into the session. the dow is up 42 points, and let's look at the winners headed by d. >> merck. goldman sachs, jp jpmorgan. stuart: and chevron's there. s&p 500 winners, who's that? >> gm. halliburton, merck, dupont and tesla. stuart: tesla's on there too. >> value plays. stuart: yep. nasdaq winners, craft heinz -- >> and dollar tree, it's no longer a buck, a dollar store, it's $1.25. stuart: the big board now shows a gain of 30 points in the early going. the 10-year treasury, is it still just below 1.50? yes, it is. 1.495. bitcoin, last time we checked it was 47,000, thousandst 48,000 -- 47,000. and price of oil, $77 a barrel. the opec meeting starts today. they may decide to pump some more oil, we'll see. nat gas, whoa, here we go, up 6%, that means it's way back, very close to $6 per mi